Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Biomarker Discovery & Validation › Merus, Elevation Oncology Advance Drug Candidates Targeting NRG1 Fusion-Positive Cancers

Merus, Elevation Oncology Advance Drug Candidates Targeting NRG1 Fusion-Positive Cancers

Jul 31, 2020
|
Charlotte Hu
Premium

NEW YORK – NRG1 gene fusions, rare alterations found most commonly in lung and pancreatic cancers, have attracted the attention of several drugmakers as a new indication for precision oncology therapeutics worthy of pursuit.

Startup Elevation Oncology and drug developer Merus both announced this month they were advancing cancer drugs targeting NRG1 fusions.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Sep
10
Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Sponsored by
Genecentric

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

What's Popular?

In Cancer

  1. Research Advocates, Leading Docs to Expand Precision Medicine Access With Decentralized Model

    Premium

  2. Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

  3. Hemogenyx Partners With UPenn to Study CAR T-Cell Therapy in AML

  4. Real-World Data Reinforces Survival Benefit of Sequential Gilotrif, Tagrisso in EGFR-Mutated NSCLC

  5. Caris Life Sciences, Elevation Oncology Partner on Patient Enrollment for Tumor-Agnostic Drug Trial

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.